[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Encouraging Israeli vaccine data", "description": "Estimating the effectiveness of the Pfizer COVID-19 BNT162b2 vaccine after a single dose. A reanalysis of a study of \u2018real-world\u2019 vaccination outcomes from Israel\n\nAnalysis completed 1st February\n\nhttps://www.medrxiv.org/content/10.1101/2021.02.01.21250957v1?fbclid=IwAR1mnoVZiabuYtzRCsJhwDGmiOeT2yKfbHLbF6b2kx7tWPwQiDEMEGViTtI\n\nNorwich Medical School \n\nWe extract the primary data from Israel to,\n\nestimate the incidence per day for each day after the first injection\n\nN = 500,000\n\nRetrospective cohort study \n\nInfections over first 24 days = 3,077\n\nDays 0 to 8\n\nCase numbers increased (x 2)\n\nDay 0 to day 14\n\nEstimated vaccine effectiveness was pretty much zero\n\nDay 8 to day 21\n\nNew cases declined\n\n\nAt day 21\n\nVaccine effectiveness, 91%\n\nAfter day 21\n\nRemained at 90%\n\nExpected to last form 9 weeks to 6 months\n\nConclusion\n\nA single dose of vaccine is highly protective\n\nThe early results coming from Israel support the UK policy of extending the gap between doses\n\nAlso\n\nVaccine effectiveness seems to be better at reducing severe disease that at reducing mild disease\n\nTherefore, more than 90% protection against severe disease, hospitalisation and deaths\n\nJapan\n\nhttps://news.trust.org/item/20210219031629-aeqnu/\n\nConfirmed 91 VOC cases, E484K mutation\n\nInfection cluster, Tokyo immigration facility\n\nIt may be more contagious than conventional strains, \n\nand if it continues to spread domestically,\n\nit could lead to a rapid rise in cases\n\nOther VOCs, 151\n\nUK data \n\nhttps://coronavirus.data.gov.uk/details/cases\n\nCases, + 12,057 = 4,083,242\n\nDeaths, + 454 = 119,387\n\nDeaths, + 7,820 = 129,498\n\nVaccinations\n\nFirst dose, 16,423,082\n\nSecond dose, 573,724\n\nW/E 14 February, 2,908,155\n\n\nUS, CDC data\n\nhttps://covid.cdc.gov/covid-data-tracker/#trends_dailytrendscases\n\nPast 7 days\n\nhttps://www.washingtonpost.com/graphics/2020/national/coronavirus-us-cases-deaths/?itid=sf_coronavirus\n\nNew daily reported cases, down 28.1%\n\nNew daily reported deaths, 26.4%\n\nCoViD related hospitalizations, down 16.1\n\n(62,300)\n\nTest positivity rate, 5.1%\n\nVaccine doses since 14th December, 58,702,000\n\nTwo doses, 16,414,000 (5.02%)\n \nhttps://covidtracking.com/data\n\n\nGlobal vaccine tracker\n\nhttps://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/\n\nUK vaccine tracker\n\nhttps://coronavirus.data.gov.uk/details/vaccinations\n\nUS vaccine tracker\n\nhttps://covid.cdc.gov/covid-data-tracker/#vaccinations\n\nEurope vaccine tracker\n\nhttps://data.spectator.co.uk/city/vaccines\n\n\nUK vaccine donations\n\nUK has ordered 400 million doses\n\nhttps://www.bbc.co.uk/news/uk-politics-56117120\n\nPM, G7, donate most of the UK's surplus vaccine supply to poorer countries\n\nNumbers going will depend on boosters required\n\nUrges 100-day vaccine target\n\nEmmanuel Macron, 4 to 5%\n\n James Cleverly\n\nlooking at a figure significantly greater than that\n\nNo short-term diplomatic leverage\n\nglobal force for good\n\nUnlike some countries\n\nPartly using Covax\n\nUK, \u00a3548m\n\nUS, $4bn", "link": "https://www.youtube.com/watch?v=Xo2QQTmbECQ", "date_published": "2021-02-19 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Human Challenge studies", "description": "COVID-19 Human Challenge studies\n\nhttps://www.gov.uk/government/news/worlds-first-coronavirus-human-challenge-study-receives-ethics-approval-in-the-uk\n\nhttps://ukcovidchallenge.com/covid-19-volunteer-trials/\n\nSpecially convened Research Ethics Committee\n\nConvened by the HRA; it was not deemed by the MHRA to be within remit\n\nImperial College London, Dr Chris Chiu, the chief investigator\n\nhttps://www.hra.nhs.uk\n\nhttps://www.hra.nhs.uk/about-us/news-updates/covid-19-human-infection-challenge-vaccine-studies/\n\nNinety, aged between 18 and 30\n\nTest efficiency of vaccines\n\nSecond generation vaccines\n\nImmunological reactions\n\nTransmission characteristics\n\nViral infective dose\n\nAdministered in liquid form, into the volunteer's nostrils\n\nRoyal Free Hospital in north London\n\nIsolated room for two and a half weeks\n\nThen monitored for up to a year. \n\nRisk of outdoor transmission of Covid-19 is low\n\nProfessor Mark Woolhouse, Infectious Disease Epidemiology, University of Edinburgh\n\nThere's been very, very little evidence that any transmission outdoors is happening in the UK\n\nThere were no outbreaks linked to crowded beaches\n\nAvoid pinch points, travel, cafes\n\nhttp://www.healthdata.org/sites/default/files/files/Projects/COVID/2021/102_briefing_United_States_of_America_0.pdf\n\nFebruary 12, 2021 \n\nUS daily cases have declined sharply\n\nNext four months, balance of four factors\n\n(Many different outcomes possible)\n\nVaccination (71% prepared to accept)\n\nDeclining seasonality, now until August\n\nSpread of variant B.1.1.7\n\nIncreased transmission behaviour\n\nDaily case decline, vaccination increases, = behaviors to increased transmission\n\nInfections are expected to increase after mid-March at least for 4-6 weeks\n\nCases, decline until mid-March, then increase to over 200,000 again by early April\n\nStress on hospital capacity in some states\n\nDeaths not increasing due to vaccination\n\nDeaths by 1st June\n\nVaccinations, 145 million adults (preventing 114,000 deaths)\n\nDeaths, 616,000\n\nDaily deaths should continue to decline\n\nMask wearing, 76% (always wore a mask when leaving home)\n\nUniversal mask coverage (95%) = 34,000 fewer cumulative deaths\n\nUnknown protection of previous infection to VOC B.1.351\n\nCurrent situation \n\n18% of people in the US have been infected as of February 8\n\n59 million\n\nCumulative infection rates greater than 25%: North Dakota, Nebraska, Iowa, and New York\n\nSouth Africa uses Johnson & Johnson\n\nUnused, 1 million doses of the Oxford/AstraZeneca\n\nFirst batch of 80,000 doses landed in the country from Brussels late Tuesday\n\nSingle dose, stored in refrigerators\n\nUS, Johnson & Johnson\n\nOnly a few million doses in stock\n\nCommitted to providing 100 million doses by June\n\nUS, Pfizer and Moderna\n\nPromised to deliver 200 million doses by the end of March\n\nSo far, 72 million doses have been shipped around the U.S\n\nHERA incubator programme\n\nEU proactive in second generation vaccine development\n\nUrsula von der Leyen\n\nThe virus has evolved and will continue to evolve\n\nIt is important we prepare for mutations\n\nAlready-authorised, AstraZeneca, Pfizer/BioNTech, Moderna\n\nJohnson & Johnson, EMA by middle of March\n\nCroatia\n\nIn talks for 1 -2 million doses of Sputnik V\n\n(Not yet been approved by EMA)\n\nHungary is currently using Sputnik V\n\nTourism needed\n\n\nSouth Africa\n\nAdrian Gore, CEO of health insurer Discovery\n\nThe number of people who have been infected, in our view, is probably over 50% of the country\n\nMost of excess deaths attributable to Covid-19\n\nNational Blood Service\n\nEastern Cape, 63% have been infected\n\nKwaZulu-Natal, 52%\n\n\nTaiwan\n\nHealth minister Chen Shih-chung\n\nCrucial deal to acquire the Pfizer/BioNTech vaccine had failed at the final step\n\nI was worried about interference from external forces\n\nI was worried about political pressure\n\nWe believed there was political pressure\n\nThe deal fell through... because someone doesn't want Taiwan to be too happy\n\nGerman firm BioNTech, struck a deal with Shanghai-based Fosun Pharmaceutical Group to bring the vaccine to China", "link": "https://www.youtube.com/watch?v=Qr6Tn5DU_Sw", "date_published": "2021-02-18 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]